Ascendis Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.11.24	Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases (GlobeNewswire)
08.10.24	Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years (Benzinga)
24.09.24	Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years (Benzinga)
20.09.24	Ascendis Pharma Prices Public Offering Of 2 Mln ADSs At $150.00/ADS (RTTNews)
19.09.24	Ascendis Pharma Commences Underwritten Public Offering Of $300 Mln Of ADSs (RTTNews)
16.09.24	Ascendis Pivotal ApproaCH Study Of TransCon CNP In Achondroplasia Meets Primary Goal; Stock Up (RTTNews)
12.09.24	Ascendis Pharma Gets U.S. Orphan Drug Exclusivity For YORVIPATH In Adult Hypoparathyroidism (RTTNews)
04.09.24	Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In (Benzinga)
04.09.24	Why Ascendis Pharma Stock Tumbled by 11% Today (MotleyFool)
04.09.24	Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut (Benzinga)
04.09.24	Ascendis Pharma Reaches $150 Mln Royalty Funding Agreement With Royalty Pharma; Stock Drops (RTTNews)
02.09.24	Ausblick: Ascendis Pharma (spons ADRs) mit Zahlen zum abgelaufenen Quartal (finanzen.net)
18.08.24	Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out (RTTNews)
12.08.24	Ascendis Rises In Pre-market On FDA Approval Of Yorvipath To Treat Hypoparathyroidism (RTTNews)
12.08.24	Ascendis Pharma Announces FDA Approval Of YORVIPATH - Quick Facts (RTTNews)
29.07.24	Biotech Stocks Facing FDA Decision In August 2024 (RTTNews)
18.07.24	$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today (Benzinga)
05.07.24	Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday (Benzinga)
05.07.24	Pendopharm Reaches Distribution Agreement With Ascendis For TransCon Parathyroid Hormone In Canada (RTTNews)
03.07.24	Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today (Benzinga)
26.06.24	Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years (Benzinga)
06.05.24	$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today (Benzinga)
01.05.24	Ausblick: Ascendis Pharma (spons ADRs) informiert über die jüngsten Quartalsergebnisse (finanzen.net)
30.04.24	Biotech Stocks Facing FDA Decision In May 2024 (RTTNews)
24.04.24	Ascendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic Hypoparathyroidism (RTTNews)
18.04.24	$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today (Benzinga)
03.04.24	Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years (Benzinga)
14.03.24	Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today (Benzinga)
06.02.24	Ausblick: Ascendis Pharma (spons ADRs) präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
05.02.24	Biotech High-Flyers That Just Hit 52-Week Highs (RTTNews)
02.02.24	$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today (Benzinga)
08.01.24	Specialised Therapeutics Signs Deal With Ascendis For Commercialization Of 3 Endocrinology Therapies (RTTNews)
11.12.23	Ascendis Pharma Says FDA Accepts Resubmitted NDA For TransCon PTH In Adults With Hypoparathyroidism (RTTNews)
06.11.23	Ausblick: Ascendis Pharma (spons ADRs) präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
16.10.23	ASCENDANT ANNOUNCES APPOINTMENT OF MR. VAL COETZEE AS DIRECTOR OF PROCESS ENGINEERING (PR Newswire)
05.09.23	ASCENDANT RESOURCES ENTERS TENDER PHASE FOR MANDATED LEAD ARRANGER FOR ITS EXPORT CREDIT AGENCY SUPPORTED PROJECT FINANCING AT ITS LAGOA SALGADA PROJECT IN PORTUGAL (PR Newswire)
04.09.23	Ausblick: Ascendis Pharma (spons ADRs) vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
23.08.23	Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders (PR Newswire)
21.08.23	Erste Schätzungen: Ascendis Pharma (spons ADRs) gewährt Anlegern Blick in die Bücher (finanzen.net)
01.08.23	ASCENDANT RESOURCES EARNS 80% INTEREST IN THE LAGOA SALGADA PROJECT IN PORTUGAL AND FILES FEASIBILITY STUDY (PR Newswire)
26.07.23	ASCENDANT RESOURCES ANNOUNCES POST-TAX NPV8 OF US$147 MILLION AND 39% IRR FROM INITIAL FEASIBILITY STUDY AT ITS LAGOA SALGADA PROJECT IN PORTUGAL (PR Newswire)
17.07.23	ASCENDANT RESOURCES ANNOUNCES DATE OF ANNUAL SHAREHOLDERS' MEETING (PR Newswire)
05.07.23	ASCENDANT ANNOUNCES POTENTIAL EXPORT CREDIT AGENCY SUPPORT FOR PROJECT FINANCE AT ITS LAGOA SALGADA PROJECT IN PORTUGAL (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Ascendis Pharma (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten